Tarsus Pharmaceuticals (TARS)

• Market cap: $2.1B
• 1 day: 0.54%
• 5 days: -11.44%
• 1 month: -8.7%
• 3 months: 20.76%
• 6 months: 4.99%
• Year to date: -9.59%
• 1 year: 56.4%
• 5 years: 142.27%
• 10 years: 142.27%
• Sector: Healthcare
• Industry: Biotechnology

About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Employees: 323

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

70% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 50

52% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 29

6% more funds holding

Funds holding: 191 [Q1] → 203 (+12) [Q2]

5.09% more ownership

Funds ownership: 104.7% [Q1] → 109.79% (+5.09%) [Q2]

17% less capital invested

Capital invested by funds: $2.24B [Q1] → $1.87B (-$369M) [Q2]

43% less funds holding in top 10

Funds holding in top 10: 7 [Q1] → 4 (-3) [Q2]